<DOC>
	<DOCNO>NCT00874770</DOCNO>
	<brief_summary>The purpose study identify 1 dos daclatasvir , use combination pegylated interferon alpha ribavirin , safe demonstrate sufficient anti-hepatitis C virus activity .</brief_summary>
	<brief_title>Safety Efficacy Daclatasvir ( BMS-790052 ) Plus Standard Care ( Pegylated-interferon Alpha Ribavirin )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Key Patients chronically infect hepatitis C virus ( HCV ) genotype 1 HCV RNA viral load â‰¥10*5* IU/mL ( 100,000 IU/mL ) screen Treatment naive Key Women childbearing potential Cirrhosis Coinfection HIV hepatitis B virus</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Antivirals</keyword>
</DOC>